Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Prey

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2010
What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literatureE Puzenat, V Bronsard, S Prey, et al.
The British Journal of Dermatology|April 20, 2012
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in FranceA Maza, M A Richard, F Aubin, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2022
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitorsE Gefard-Gontier, R Markich, M Zysman, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2010
What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literatureE Puzenat, V Bronsard, S Prey, et al.
The British Journal of Dermatology|April 20, 2012
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in FranceA Maza, M A Richard, F Aubin, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2022
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitorsE Gefard-Gontier, R Markich, M Zysman, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 3